Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    Important update:The value on the webpage regarding Voydeya has been updated from receiving regulatory approval in Japan for use in combination with C5 inhibitor therapy to being recommended for approval in the EU as an add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic anaemia. This change signifies a shift in the approval status of Voydeya, indicating progress towards potential approval in the EU for a specific patient population with PNH.
    Difference
    6%
    Check dated 2024-02-27T06:42:27.000Z thumbnail image
  6. Check
    9 days ago
    Change Detected
    Summary
    Important update:The recent change on the webpage from "Beyfortus approved in China for the prevention of RSV disease in infants 02 January 2024" to "Acquisition of Gracell completed 22 February 2024" signifies a shift in focus from the approval of a specific product to the completion of an acquisition deal involving Gracell. This change likely reflects a significant development in the company's strategic direction or expansion efforts, as indicated in the Announcement, News, or Press Release section of the webpage.
    Difference
    3%
    Check dated 2024-02-23T02:01:12.000Z thumbnail image
  7. Check
    13 days ago
    Change Detected
    Summary
    Important update:The recent update on the webpage indicates that Tagrisso with the addition of chemotherapy has been approved in the US for patients with EGFR-mutated advanced lung cancer, as of February 19, 2024. Additionally, positive high-level results from the Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) have been reported, showing consistency with the global ATTRibute-CM Phase III trial on February 2, 2024.
    Difference
    13%
    Check dated 2024-02-19T22:40:37.000Z thumbnail image
  8. Check
    15 days ago
    Change Detected
    Summary
    Important update:The recent change on the webpage now reflects the approval of Tagrisso with the addition of chemotherapy in the US for patients with EGFR-mutated advanced lung cancer on February 16, 2024. This update signifies a significant development in the treatment options available for individuals with this specific type of lung cancer, potentially impacting patient care and outcomes.
    Difference
    6%
    Check dated 2024-02-17T21:32:04.000Z thumbnail image
  9. Check
    24 days ago
    Change Detected
    Summary
    Important update:The change on the webpage represents the latest press releases from AstraZeneca, including positive high-level results from a Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in Japan, the granting of Priority Review for Enhertu in the US for patients with metastatic HER2-positive solid tumors, and the reduction of risk of disease progression or death by 23% with Imfinzi plus transarterial chemoembolization (TACE) and bevacizumab in liver cancer eligible for embolization.
    Difference
    49%
    Check dated 2024-02-08T10:53:20.000Z thumbnail image
  10. Check
    25 days ago
    Change Detected
    Summary
    Important update:The change on the webpage represents the addition of two press releases. One press release announces positive high-level results from a Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in Japan, showing consistency with a global trial. The other press release states that Enhertu has been granted Priority Review in the US for patients with metastatic HER2-positive solid tumors.
    Difference
    36%
    Check dated 2024-02-07T10:22:05.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.